Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]

NCT07695298 is registered in ClinicalTrials.gov with Cincinnati Eye Institute, Southwest Ohio as lead sponsor.

NCT NCT07695298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07695298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome [PLANE Study]
Lead sponsor
Cincinnati Eye Institute, Southwest Ohio
Phase
Phase 4
Overall status
Recruiting
Start date
July 31, 2026
Completion date
May 31, 2028
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

presumed ocular histoplasmosis